XL
Xue-song Li

Publications (1)

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
Article scientifique · 2017

Domaines principaux

Sciences de la santé1

Statistiques

Consultations2
Téléchargements0